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ABSTRACT
The thiol protease inhibitor (TPI— d) from hindlimb
skeletal muscle of 60 day old dystrophic male mice (strain
129/ReJ—dy ) and thiol protease inhibitor (TPI—h ) from the
skeletal muscle of 9 months old carrier females, heterozygous
for the disease, have been purified to apparent homogeneity
and compared with the thiol protease inhibitor (TPI—n) from 60
day old normal male

1 ittermates

and thiol protease inhibitor

(TPI— c) from 9 month old normal retired breeders.

While

TPI—d, TPI—n, TPI— h and TPI— c all displayed identical
properties on SDS—polyacrylamide gels (Mr 14,800), analytical
isoelectric focusing gels (pi 4.5), and high performance
liquid chromatography columns, TPI—d was unable to inhibit
papain and cathepsin B after purification by isoelectric
focusing.

However, a component in the apparently purified

TPI—d preparation with a pi of 4.9 masked the functional state
of TPI—d when papain or cathepsins H and L were used as test
proteases.

This inhibitory component was also observed in the

TPI-h preparation from carrier females.

However, TPI-h

inhibits cathepsin B activity to the extent observed with
inhibitor preparations from normal muscle. The inhibitory
component of pi 4.9 was absent from TPI—n and TPI—c
préparâtions.

Pure TPI— d was also unable to inhibit myosin

hydrolysis i.n_yitrg by cathepsin B, whereas TPI—n completely
blocked cathepsin B catalyzed myosin hydrolysis.

Given the

central role of the thiol proteases, especially cathepsin B,
in intracellular protein metabolism, and the possibility that

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

uncontrolled thiol .protease activity in muscle leads to muscle
protein breakdown and dystrophy, this study suggests that the
thiol protease inhibitor in dystrophic mouse muscle (TPI— d)
may be (one of) the end—product(s) of the dystrophy gene in
mice with the hereditary form of the disease.

V I
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I.

INTRODUCTION

The metabolic disorders known as muscular dystrophies
are a heterogeneous group of disorders characterised by muscle
weakness and degeneration (Knudson, 1965).

Muscular

dystrophies are regarded as primary myopathies; the lesion(s)
is(are) presumed to be present and expressed in the muscle
itself (Perry, 1984).

Dystrophic tissues exhibit a gradual

deterioration of function associated with progressive necrosis
and often, in the early stages of the disease, certain muscles
which are characteristic of the type of dystrophy, are
specifically affected.

One of the most severe forms of the

disease is the X—linked form known as Duchenne muscular
dystrophy (DMD) which affects mainly young males.

The DMD

locus in humans is at position Xp 21 on the X— chromosome
(Jacobs et al., 1981).

In humans the disease is usually

diagnosed clinically by about age 3—5, while in mice and
chickens the expression of the disease begins around 2—3 weeks
ex—utero (Walton and Nattras, 1954).

Histological

examinations of muscle in the early stages of Duchenne
muscular dystrophy have revealed differences in the
organization of the contractile elements compared to normal
muscle.

As the disease progresses many muscle fibres show

extensive degeneration, the sarcolemma shows areas of
discontinuity and there is a disproportionate increase in
connective tissue and fat cells in severely affected muscle
(Cazzato, 1968; Hunters, 1980).

Numerous other morphological

changes have been reported in the various forms of dystrophy

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

(Cullen and Mastaglia, 1980).
During the past 20 years several hypotheses have been
advanced to explain the pathogenesis of muscle in laboratory
animals and Duchenne muscular dystrophy patients.

These

include the vascular hypothesis (Sweeney and Brown, 1981),
neurogenic theory (Desmos, 1961), membrane theory (McComas et
al. 1978), myogenetic theory (Witkowski and Jones, 1981) and
connective tissue theory (Lucy, 1980).

While there are

abundant experimental data to support each of these views, it
is not yet clear whether the observations which led to these
hypotheses are primary or secondary process(es) of the
disease. The biochemical nature of muscular dystrophy is
poorly understood.

Thus the cause(s) of the myriad of

biochemical alterations which occur(s) in dystrophic animals
has(have) not been identified.

A . yse_gf_animal_mgdels_tg_study_the_disease_Brgçess
A disease in experimental animals which simulates both
morphologically and clinically a disease process in humans,
does not indicate, a priori, that the etiology or pathology of
the experimental animal and human disease are the same (Bajusz
et al., 1966). The value of the experimental model in
elucidating the etiology and pathogenesis of human diseases
becomes apparent only when it can be shown that the responses
to a variety of stimuli of animal/tissue under investigation
are identical or similar to that in the human.

Differences in

tissue response per se indicate a difference in pathogenesis
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and warn the investigator of the degree of its possible
existence

(Bajusz et al., 1966). Therefore the greater the

difference in response, both clinically and morphologically
between the experimentally induced disease and the disease in
humans, the greater the likelihood of etiological and
pathogenetic

differences.

By the intelligent use of

experimental models and a variety of experimental techniques,
the possibility exists that greater insight into human disease
processes may be obtained.

Despite the fact that inherited

forms of muscular dystrophy were first described in the mouse
and chicken more than 4 decades ago, and in the hamster in
1962,

the debate continues regarding their relevance to human

forms of muscular dystrophy (Mendel1 et al., 1979;

Watts and

Reid, 1969; Bradley and Jenkinson, 1975 ; Johnson and
Montgomery, 1976; Jasmin and Bokdawala, 1970).

The

controversy will probably continue until specific biochemical
defects are identified which can be used as a basis for
comparison between human and animal forms of muscular
dystrophy.

B.

Murine muscular dustrophu
Murine Muscular dystrophy was first observed as a

spontaneous autosomal mutation in strain 129/ReJ (Michelson et
al., 1955) causing muscular weakness, atrophy and reduced life
span

characteristic of myopathy.

In mice there are a number

of clinical, histological and pathological similarities to DMD
in humans, except for the difference in inheritance, which is
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autosomal.

Clinically, dystrophic mice can be identified by

their abnormal behaviour at about 2 weeks of age.

Clinical

signs are muscular weakness, periodic dragging of the rear
feet, clasping of the hindlimbs when the animal is suspended,
and spasmodic gaping or nodding of the head (Russell, 1961).
Also, the dystrophic mice are much smaller than their normal
litter mates (see Fig la) and the leg muscles weigh about one
half that of the normal mice (Gopalan et al., 1986a).

Fig. lb

shows the leg musculature of normal and dystophic mice. In
certain stocks,

afflicted animals often show tetanic

seizures which are not usually lethal.

If dystrophic mice

live long enough, they develop permanent paralysis of hind
limbs and severe contractures.

Very old dystrophic mice often

develop and die of pneumonia (Russel and Meier, 1979).
Extensive investigations have defined structural
details of muscle fibre breakdown in murine dystrophy (Platzer
and Powell,

1975).

According to Platzer and Powell the

earliest identifiable ultrastructural change is seen in the
sarcoplasmic reticulum which becomes dialated.

This change is

fallowed sequentially by the appearance of fragmented
myofibrils which are out of register, and swollen spherical
mitochondria which contain irregularities in the cristae and
some electron dense areas in the matrix.

With continued

muscle fibre breakdown, the fibres show retraction clots,
sparsity of cellular organelles, including the T—system,
myofibrillar fragmentation and further sarcolemmal breakdown,
leading finally to phagocytic infiltration.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Figure la.

Photograph of normal and dystrophic mice.

Note

the reduced size of the dystrophic mouse (right)
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Figure lb.

Photograph showing the hind leg muscles of
normal and dystrophic mice.
Top:

Hind leg muscles from normal mouse.

Bottom:

Hind leg muscles from dystrophic mouse.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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In the mouse, the individual pattern of muscle fibre
breakdown occurs in an entirely different setting than that
seen in the hamster (Mendel1 et al., 1979). The degenerating
fibres are usually randomly distributed as either isolated
fibres or as two or three together.

There are, however, areas

of the muscle that display preferential involvement in the
process.

In the 129/ReJ dy/dy strain, the crown position of

the anterior tibialis, composed of predominantly fast twitch
glycolytic fibres, appears to be the site of primary
expression of the disease.

In C57BL/dy^*^/dy^*^ strain, the

target is believed to be the slow twitch oxidative fibres of
the core portion of the anterior tibialis and soleus muscles.
The initial stage of muscle fibre breakdown appears to
involve partial or complete segments of muscle fibres.

These

areas of the muscle fibre are then invaded by macrophages.
Before phagocytosis is complete, evidence of muscle fibre
regeneration ensues with the appearance of presumptive
mononuclear myoblasts, which apparently fuse to form
regenerating fibres (West and Murphy,

1960).

It is during the latter stage of regenerative activity
that murine dystrophy shows singular differences from the
hamster form of the disease.

In association with the muscle

fibre régénérâtion, proliferation of the endomysial connective
tissue is quite prominent.

West and Murphy (1960) describe

this phenomenon as an "early sequela to regenerative activity"
which they believe is the result of newly proliferated
connective tissue rather than condensation of existing
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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endomysium.

The final stages of murine dystrophy are

characterised by marked variability in muscle fibre size, and
significant endomysial connective tissue proliferation, which
surrounds smaller diameter fibres.

Fatty replacement is not a

prominent feature; however, it can be enhanced by prolonging
the life span of the animal (Mendel1 et al., 1979).

C.

ÇgmBarisgn_of_dystrgBhy_in_miçe_and_humans
In humans, in yitrg studies show that the early stages

of muscle fibre breakdown are associated with extensive
leakage of horseradish peroxidase into muscle fibres (Mendel1
et al., 1979). The small wedge-shaped pattern of horseradish
peroxidase leakage observed in hamster and Duchenne human
dystrophy is not seen in murine dystrophy. However, in the
mouse, horseradish peroxidase infiltration is usually more
extensive, suggesting that larger segments of the plasma
membrane are affected during muscle fibre dégénérâtion. This
conclusion is consistent with previous ultrastructural reports
on mouse dystrophy which describe alterations in sarcoplasmic
organelles prior to breakdown of the cell membrane (Platzer
and Powell, 1975).

Accumulation of calcium deposits and other

signs of cell damage support the conclusion that focal defects
in the plasma membrane are probably not the initial events in
cellular degeneration in murine dystrophy. However,
identification of both horseradish peroxidase leakage and
calcium influx during early cellular necrosis (prior to
phagocytosis) may have relevance to the pathogenesis of muscle
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fibre breakdown in some types of human muscular dystrophies,

D.

Syrian_hamster_^stroBhy
Syrian hamsters suffering from hereditary muscular

dystrophy develop acute cardiac muscle lesions in addition to
skeletal muscle breakdown. The acquisition of knowledge
concerning involvement of the heart in progressive muscular
dystrophy, and in other forms of primary myopathies is
important from several viewpoints. Ignorance of this subject
may lead not only to incorrectly identified clinical symptoms,
but also to inaccurate etiological diagnosis and treatment.
From a pathophysiological viewpoint, cardiac involvement is of
great interest in respect to both its haemodynamic effect per
se and the underlying mechanisms of heart failure.
Furthermore, studies of this type of cardiac condition provide
an opportunity to gain information concerning differences in
susceptibility between cardiac and skeletal muscles, since
virtually nothing is known about the factors that determine
which of these two muscle systems will undergo degeneration in
any given set of pathological circumstances (Bajusz et al.,
1966). From a biochemical viewpoint, an analysis of the
altered myocardial metabolism may elucidate the primary
biochemical lesion responsible for the disease in striated
muscles.

In view of these considerations, studies of cardiac

muscle lesions which develop in 100% of the Syrian hamsters
suffering from hereditary muscular dystrophy become important.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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In a large percentage of these animals (ca. 90%), cardiac
involvement progresses to congestive heart failure.

The gross

and histopathological abnormalities seen outside the skeletal
and cardiac muscles in the myopathic hamsters are consistent
with chronic passive venous congestion, and the progressive
cardiovascular insufficiency
cause of death.

may be regarded as the ultimate

Thus, the inbred line of Syrian hamsters

provides not only an opportunity to study the involvement of
the cardiovascular system in a genetically determined primary
myopathy, but it also presents a useful and unique disease
model for analysis of the underlying mechanism of congestive
heart failure.

The slow progression of the

cardiovascular

condition in the myopathic hamsters and high incidence of
congest ive heart failure within the homozygous line offers new
possibilities for investigative cardiology.
The initial stages of individual skeletal muscle fibre
breakdown are characterised by a series of changes in the
myofilaments and mitochondria.

Under the light microscope the

mitochondria appear swollen and often clumped together, and
the muscle fibres have lost their normal striations usually
appearing hyalinized or hypercontracted. This stage is soon
followed by the presence of macrophages surrounding and
finally invading the fibre (Mendel1 et al., 1979). At the
ultrastructural level, the mitochondria display a spectrum of
changes accompanying the early events.

The clumping of

mitochondria seen in the light microscope is quite apparent.
The mitochondria become spherical rather than elongated in
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appearance and they are often larger than normal.

The cristae

are indistinct or absent in some mitochondria, while in others
they exhibit parallel and concentric arrays.

Concommitent

with histological changes, myofilaments ultimately become more
fragmented and randomly oriented.

Initially, the A bands are

preferentially spared, while there is a complete absence of
the Z bands.

Accompanying the initial stages of muscle fibre

breakdown, but proceeding phagocytosis, are intracellular
accumulations of granular material seen with alizarin red
stain for calcium (Mendel1 et al., 1979). Some fibres
demonstrate granular deposits restricted to the subsarcolemmal
regions while in others, calcium deposits are observed to be
distributed throughout the cross sectional diameter of the
fibre (Mendel 1 et al., 1979).
Various stages of horseradish peroxidase leakage into
muscle fibres were observed corresponding to the

stages of

muscle fibre breakdown. The earliest detectable change that
preceded phagocytosis was leakage into the subsarcolemmal
region, which could be seen in the light and electron
microscope.

The area of leakage was often restricted to a

small wedge shaped area with the base toward the periphery or
in the form of a restricted subsarcolemmal band of horseradish
peroxidase.

The area of wedge shaped leakage displayed a loss

of overlying plasma membrane with preservation of the basement
membrane.

In advanced stages of muscle fibre breakdown,

leakage of horseradish peroxidase extended further into the
sarcoplasm (Mendel1 et al., 1979).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

14

E.

ÇomBarisgn.gf_dustrBBhu_in_hamsters_aDd_humaQi
The initial stages of skeletal muscle fibre breakdown in

the hamster have certain similarities to Duchenne muscular
dystrophy (Mokri and Engel, 1975; Bodensteiner and Engel,
1977).

The early leakage of horseradish peroxidase in a

wedge-shaped pattern in the muscle fibre is similar to that
described by Mokri and Engel in humans (1975). This finding
suggests that the plasma membrane is disrupted as one of the
early morphological events in muscle fibre breakdown in the
hamster.

This occurence is different from that observed in

Duchenne muscular dystrophy where the breakdown of the plasma
membrane accompanies, rather than precedes, other alterations
in the muscle fibre (Mendel1 et al., 1979).

The early

accumulation of calcium deposits in the muscle fibre is also
similar to that found in Duchenne dystrophy (Bodensteiner and
Engel, 1977). A significant distinguishing feature, however,
is that groups of muscle fibres rich in calcium deposits are
far more extensive in the hamster, and overt mineralization of
the mitochondria is not a prominent feature of human
dystrophy.
Several additional points of morphological differences
from human dystrophy have been observed in the hamster.
Groups of muscle fibres undergoing necrosis and regeneration
have been seen in Duchenne muscular dystrophy (Karpati et al..
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1974), but they never reach the extensive size seen in the
hamster where they can often be visualized grossly (liende11 et
al., 1979). Furthermore, the marked degree of phagocytosis in
the hamster is a far more subtle feature in human dystrophy.
In addition, the presence of intracristal plates in the
mitochondria of degenerating fibres in the hamster are rarely
seen in Duchenne dystrophy (Karpati et al., 1974). The final
point, and one that more clearly distinguishes the dystrophic
process in the hamster from that in humans (aside from the
fact that dystrophy affects primarily the cardiac muscle in
hamsters) is the absence of endomysial connective tissue
proliteration and fat infiltration in the hamster. The
degenerative process in the hamster simply does not seem to
reach this stage (Mendel1 et al., 1979).

F.

Muscular_dystroBhy_in_the_çhiçkens
Myopathy in chickens is characterized principally

by a

failure in the development of fast twitch glycolytic fibres in
the pectoral is muscles shortly after hatching (Cosmos and
Butler, 1967). This developmental failure may occur through an
inability to respond to neurotropic influences mediated by a
defective sarcolemma.

However, evidence that the fetal spinal

cord imprints a dystrophic character on the pectoral is muscle
at a very early stage has also been obtained (Rathbone et al.,
1975). A rapid reversal of metabolic behaviour to a fetal
fibre type occurs during the first 2 weeks ex—gyg.
Subsequently, the pectoral is displays a marked pseudo—
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hypertrophy, phagocytosis of individual fibres and an increase
in connective adipose tissue (Owens, 1979).
Horseradish peroxidase studies in dystrophic chicken
muscle showed that the vacuoles in the individual muscle
fibres, studied by light and electron microscopy, communicate
with the extracellular spaces.

The limiting membrane,

distinct in some places, usually could not be traced around
the entire vacuole.

In addition, the foci of the myofibrillar

disarray begin rather abruptly.

The Z-band material appears

as an irregularly dispersed mass, but the Z—band streaming is
not seen.

The boundaries of A and I bands can be discerned,

and the thick and thin filaments are completely disoriented.
There are no obvious organelle
pathogenesis.

changes to give a clue to the

Muscle fibres that demonstrate myofibrillar

disarray do not show any evidence of horseradish peroxidase
leakage across the membrane (Mendel1 et al., 1979).

6.

ÇonjEar ison _of _dys trQBhy_ in_çh içkens_an d_humans
The muscle fibres in dystrophic chickens contain a marked

increase in lipid droplets. Several abnormalities like
variation in muscle fibre size, muscle fibre splitting,
increase in the number of internal nuclei, vacuolization of
fibres and scattered fibres undergoing necrosis and
phagocytosis are also seen (Mendel1 et al., 1979). In the
chicken there is no evidence in support of a significant
plasma membrane defect, either by horseradish peroxidase
leakage or by accumulation of calcium deposits, as one of the
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causes for these known abnormalities.

In this way, dystrophy

in chicken muscle shows changes unlike those observed in the
DMD disorder, where the influx of calcium apparently is the
stimulus for the muscle fibre to undergo a series of
morphological changes.

H.

Summary_gf_mgrBhglggiçal_çhanges_in_dystrgghiç_animais
cgmBared_tg_dystrgBhiç_humans
The hamster and mouse show changes of potential relevance

toward understanding the pathogenesis of individual muscle
fibre breakdown in human DMD. In both species, horseradish
peroxidase leakages and calcium deposits accompany muscle
fibre breakdown.

The chicken, in contrast, offers the

challenge of understanding the vast array of morphological
changes in the absence of a significant plasma membrane defect
as a step in the development of these changes.
no animal disease

While perhaps

model can be expected to be identical in

every way to a human disease, each has features that are
important in relationship to particular aspects of human
muscle pathology.

Furthermore, the inherited form of muscular

dystrophy in animals provides a unique opportunity to study
sequential morphological changes in the development of this
pathological process.

I.

Biochemical_characteriStics_of_dygtrgBhy
The primary biochemical lesions involved in muscular

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

18

dystrophy are not known, although, a great deal of research
has been done during the last few years. Changes in lipids
(Hughes, 1972), carbohydrate (Johnson et al., 1979), purines
(Thomson and Smith, 1978), and protein metabolism (lodice et
al., 1972; Strickland et al., 1979) have been implicated in
the onset of dystrophy. Other workers have shown that both RNA
content and synthesis are increased in dystrophic muscles of
the mouse (Srivastava, 1968; 1967; Girkin et al., 1962; Fowler
et al., 1977). However, the RNA content was found to be
decreased relative to the DNA content (Hayashi et al., 1975).
Fowler et al.(1977) observed an increase in DNA content in
dystrophic muscle of the mouse. The significance of increased
RNA and DNA levels in dystrophic muscle is difficult to
understand.

However, these increases may be due, in part, to

muscle hypertrophy, which, in turn, reflects the compensatory
attempts of dystrophic muscle.
Progressive muscular dystrophy is characterised by severe
wasting of skeletal muscle and this is confirmed by the lower
body and muscle weights of dystrophic animals (Hayashi et al.,
1975; Watts and Reid, 1969); Kitchin and Watts, 1973).

In

view of the great importance of proteins in the structure and
function of muscle, many laboratories have studied protein
metabolism in dystrophic animals.

Several studies have shown

that the total nitrogen content is decreased in dystrophic
muscle (Srivastava, 1968; Berilinguet and Srivastava, 1966;
Srivastava and Berilinguet, 1964). Also, the rate of increase
in body weight or in leg musculature of the dystrophic mouse
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is only about 50% of normal at 4-8 weeks of age (Gopalan et
al., 1986a).

However, it has been shown that non-collagen

nitrogen per gram of muscle is not altered (Nihei and
Filipenko, 1974;

Fowler et al., 1977). Since the amount of

DNA (per unit weight) in muscle is increased, it may be
concluded that the relative reduction in proteins is due
either to a decrease in protein synthesis or to an increase in
protein degradation.

Several studies designed to measure the

rate of protein synthesis in normal and dystrophic muscle have
shown that the rate of protein synthesis in intact dystrophic
skeletal muscle is elevated markedly.

In dystrophic hamsters,

the rate of total protein synthesis in_yiyo is nearly two-fold
greater than in corresponding controls, and the same is true
for myosin synthesis

(Strickland et al., 1979).

In

dystrophic mice (129/ReJ) Garber et al.(1980a) observed that
the rate of protein synthesis is nearly 5-fold greater than
litter mate controls.

When the identity of the protein

synthesized was studied using SDS-PAGE they observed that the
majority of the proteins migrating between heavy chain myosin
and actin were synthesized in similar proportion in both
normal and dystrophic muscle.

Several differences in the

relative rates of protein synthesis were observed in lower
molecular weight proteins such as myosin light chains 1, 2 and
3 and troponin I and C which all showed a reduced rate of
synthesis relative to act in and myosin, but still higher than
in the controls.

Using human muscle from Duchenne muscular

dystrophy patients, lonascescu et al.(1971) observed that
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protein synthesis in_yi.trg is 5—6 times higher than normal
controls. Their later work showing an increase in number of
membrane bound ribosomes in preparations from human dystrophic
muscle also support this view (lonasescu et al., 1981b).
However, a previous observation, contrary to these, had been
made where no difference in the ribosomal content of normal
and dystrophic muscle was noticed (Watts and Reid, 1969).
According to these workers the "machinery" for protein
synthesis appears to be normal, and any difference must be due
to altered concentrations that result from changes in muscle
volume. Yoshikawa et al. (1984) and Saleem and Nicholls
(1979)

observed an increase in the number of EF-2 molecules

in the cytoplasm of dystrophic muscle which may account for
the increase in protein synthesis activity observed in
dystrophic chickens and hamsters. Other studies indicate a
defective protein synthesis "apparatus". Nicholls et al.(1986)
have shown that the ability to translate mRNA for tropomyosin
in the dystrophic hamster muscle homogenate is decreased
compared with the normal control.

Srivastava (1969) showed

that in dystrophic muscle, incorporâtion of radioactivity into
low—molecular weight proteins like tropomyosin is higher,
while that into high molecular weight proteins like myosin is
lower than normal.

Synthesis of actin was not affected.

These findings suggest that the polyribosomal fraction from
dystrophic muscle is less active, while the monoribosomal
fraction is more active.

Several laboratories have studied
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the synthesis of myosin in dystrophic muscle (Nihei and
Filipenko, 1974; John et al., 1973; Monckton and Marusyk,
1975).

Monckton and Marusyk (1975) used autoradiography and

showed decreased myofibrillar synthesis ln_ylyg in dystrophic
muscle of humans. Nihei and Filipenko (1974) also noted a
decreased in_yiyg

synthesis of myosin in murine dystrophy.

These workers demonstrated that polyribosomes from dystrophic
muscle are more active in the synthesis of non—myosin
proteins.

A potassium chloride extract from normal

polyribosomes was found to restore the myosin synthesis
activity of dystrophic polyribosomes (Nihei and Filipenko,
1974).

Thus, there is considerable evidence to suggest that

the polyribosomal system from dystrophic muscle is deficient
in a myosin specific factor(s) and thus may be responsible for
the impaired synthesis of myosin.
In the past two decades several studies have focused on
carbohydrate metabolism in dystrophic muscle to determine
whether alterations in carbohydrate metabolism are the cause
of muscle weakening in Duchenne muscular dystrophy patients
(Strickland et al., 1979; Ellis, 1980). The published
literature on this topic has revealed that several aspects of
the glycolytic process are altered in dystrophic muscle.
First, mammalian muscle has a reduced capacity for both the
synthesis and utilization of glycogen.

This lesion appears to

be due to a marked reduction in glycogen, UDP—g 1y cosy1
transferease and glycogen phosphorylase activities (Garber et
al., 1980a; Dreyfus, 1954 ; Ellis, 1980).

Most other
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glycolytic enzymes show some reduction in activity in
dystrophic muscle.

As a result, dystrophic muscle has a

reduced capacity to produce lactate and ATP (Dreyfus,1954).
Also, the dystrophic muscle is capable of increased
utilization of glucose via hexose monophosphate shunt,
increased synthesis of NADPH and thus an increased synthesis
of lipids in dystrophic muscle has been proposed by Ellis
(1980). Garber and co-workers have also shown that dystophic
muscle has a reduced responsiveness to insulin stimulation of
glucose uptake and adeny1 cyclase activation of epinephrine
(1980b).

However, since adeny1 cyclase from dystrophic muscle

membrane can be fully activated by sodium fluoride, these
workers have suggested that the defect in the adeny1 cyclase
mechanism may be due to a defect in the adrenergic membrane
receptor or receptor coupling to adeny1 cyclase. In addition
to this, increased amino acid release especially alanine and
glutamine was observed by Garber et al. (1978).

Amino acid

formation and release seems to be modulated by the cyclic
nucleotides in association with insulin and also with other
agonists.

Catecholamines acting through a B-adrenergic

receptor and in association with increased intracellular
levels of cAMP are potent inhibitors of alanine and glutamine
formation and release in skeletal muscle (Garber et al., 1976;
Garber, 1978).
through

Serotonin (5-hydroxytryptamine) acting

D—serotonergic receptors and in association with

increased levels of cAMP, inhibits alanine and glutamine
formation and release from muscle (Garber, 1978).

The
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increase in amino acid release appears to result, in part,
from an increase in

skeletal muscle protein degradation

(Garber et al., 1980a). Increased cyclic GMP levels were found
in dystrophic muscles as compared with normal muscle by the
same workers, and these higher levels may lead to increased
rates of muscle proteolysis and hence greater alanine and
glutamine formation and release.

The apparent inability of

cAMP to inhibit amino acid output may be derived from the
augmented cGMP level in dystrophic mouse muscle since
antagonistic roles have been proposed for these cyclic
nucleotides in other biological systems (Goldberg et al.,
1973).
A symptom of muscular dystrophy of particular clinical
relevance is the high level of activity of serum creatine
kinase (Bradley and Fell, 1980).

The dramatic elevation of

serum creatine kinase activity is a diagnostic feature of
muscular dystrophy in humans, and an increase, though less
dramatic, occurs in each of the three main animal models of
the disease.

While the increase in serum creatine kinase

activity is generally assumed to be due to leakage from
diseased muscle fibres, it is by no means clear what sort or
extent of cellular damage would be consistent with the
increased serum activity.

Kuby et al.(1977) made a

remarkable observation regarding creatine kinase. They showed
by direct isolation of creatine kinase that 3 isoenzymes of
creatine kinase are present in the musculature of males
affected by terminal Duchenne muscular dystrophy, whereas only
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the muscle type was to be found in the skeletal muscle of
normal adult human males.

In human brain tissue of both the

normal and dystrophic animals, only a single isoenzyme could
be detected and isolated.

The creatine kinase isoenzymes from

dystrophic muscle were compared electrophoretically and
immunologically with isoenzyme preparations from normal muscle
(Keutel et al., 1972) and identified as muscle type, hybrid
type, and brain type.

The unique isoenzyme distribution of

the creatine kinases found in the atrophying muscle of
patients with Duchenne muscular dystrophy resembles that of
foetal muscle and this has led to the speculation that the
major biochemical defect in Duchenne muscular dystrophy may
lie in the inability to "switch off" the synthesis of
foetal-like proteins (Schapira, 1967; Schapira et al., 1968;
Eppenberger et al., 1964; Cao et al., 1968; Dawson et al.,
1968, Kuby et al.(1977)

This, in turn, might lead to a

foetal— like complement of proteins in skeletal muscles, in the
membrane of muscle, or even within the membrane of red cells.
Thus , the so-called "leaky" or "fluid" membrane abnormalities
described for the dystrophic red cell (Butterfield, 1977)
might simply be another manifestation of a more generalised
phenomenon, namely that of a foetal—type membrane composed of
a foetal—like complement of proteins.

Other proteins which

show immature isoenzyme patterns are lactate dehydrogenase
(Kaplan and Cahn, 1962; Emery, 1964; Tsvetanova and Ognianov,
1967), myosin (Obinata et al., 1980; Fitzsimons and Hoh, 1981)
and tropomyosin (Takeda and Nonumura, 1980) in dystrophic
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muscle.

The presence of foetal myosin in patients with

Duchenne muscular dystrophy probably reflects a certain amount
of

muscle régénérât ion, and immaturity of some muscle cells.

If the suggestion given by Kuby et al.(1977) bears merit,
the X-1inked Duchenne muscular dystrophy might be an inborn
error in the final development of the muscle tissue in the
human male organism such that there is a reversion back to
foetal development, or that there is a reversion back to the
foetal state in muscle prior to death.
Many other factors also seem to be impaired in
dystrophy.

Poly-ADPR synthetase decreases during normal

differentiation of muscle cell (Caplan et al., 1979).

A

delayed decrease in the amount of poly—ADPR in dystrophic
chickens suggests an abnormal developmental program (Yoshikawa
and Masaki, 1985).

Abnormal acetylcholine esterase content

has been observed in dystrophic muscle.

High levels of

acetylcholine esterase are found throughout the fibre of
normal and dystrophic embryo muscles.

This activity is

associated with several molecular forms separable on
polyacrylamide gels.

In the normal muscle, the enzyme levels

decline after hatching, cytochemical staining decreases and
low molecular weight forms of this enzyme can no longer be
detected on polyacrylamide gels.

However, in muscles

afflicted with dystrophy the embryo-1 ike forms are retained.
Moreover, acetylcholine esterase levels are high, low
molecular weight forms are present,

(seen in polyacrylamide

gels) and the acetylcholine staining is high in sarcoplasm
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outside motor end—plate regions (Wilson et al., 1970; Linkhart
and Wilson, 1975 and Wei doff and Wilson, 1977).

These

observations support the idea that there is an error in in
development and it involves processes mediated by nerve muscle
interactions.

J.

I n te g r i ty_of_ Bi as ma _m em br an e_ i n_dystr O E h iç _ a n im a 1s

The hypothesis that muscular dystrophy is primarily the
result of a membrane defect has been supported by several
observations among which are differences in ionic permeability
of the sarcolemma, decrease in nucleotide and creatine
phosphate levels, increase in serum levels of several
intracellular enzymes, and alterations in the plasma membrane
structures of several cell types.
One of the most striking features of Duchenne muscular
dystrophy in humans (as indicated earlier) and a commonly used
clinical indicator of the disease, is an elevation of serum
creatine kinase which may reach as high as fifty times the
normal plasma level in the early stages of the disease
(Munstat et al., 1973 ; Rowland, 1980).

The source of this

enzyme is thought to be due to "leaky" skeletal muscle cells
which are rich in creatine kinase.

However, there is still

controversy in the literature concerning the relevance of
creatine kinase as an indicator of Duchenne muscular dystrophy
since dystrophic human muscle cells in culture do not appear
to leak creatine kinase into the medium although the
concentration of creatine kinase is low in these cells.
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2?

the serum level of creatine kinase is not elevated in the
commonly used strain (129/ReJ) of dystrophic mice (lonasescu
et al., 1981a; Lieberman et al., 1981).

Despite apparent

strain differences, muscle appears to be the source of plasma
creatine kinase as uiell as serum aldolase in Duchenne muscular
dystrophy patients (Strickland et al., 1979; lonasescu et al.,
1981a).
Other evidence which is consistent with the view that
dystrophic cells are "leaky" comes from measurements of the
electrolyte content of normal and dystrophic muscle cells.

It

has been shown that dystrophic muscle cells have an elevated
concentration of sodium and chloride ions and a decreased
concentration of potassium ions (Strickland et al., 1979;
Duncan, 1978).

However, since the literature contains

conflicting reports on the integrity of plasma membrane ATPase
activity in dystrophic tissues, it is still not clear
whether the alterations in sodium and potassium levels in
diseased muscle are due to defective Na^/K^ ATPase
molecules in the plasma membrane

or to enhanced "leakyness"

of the membrane. The change in electrolyte distribution during
the onset of dystrophy may also be due to the appearance of
"holes" in the plasma membrane (Cullen and Mastaglia, 1980).
Regardless of the cause of this defect, the possibility that
an increase in intracellular calcium in dystrophic muscle
promotes the activity of muscle proteases capable of degrading
the myofibrillar proteins has been clearly noted (Kar and
Pearson, 1976).
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Another membrane defect which has been shown to occur in
both erythrocytes and muscle of dystrophic humans and mice is
depletion of transmembrane particles.

Freeze fracture

techniques have revealed that the plasma membrane of both
erythrocyte and myotubes have 40—60% fewer transmembrane
particles than normal cells (Cullen and Mastaglia, 1980;
Munstat et al., 1973; Shivers and Atkinson, 1979). Since these
membrane particles are involved in transport mechanism, the
disappearance of these membrane particles in dystrophy
implicates proteases in the removal of these particles and in
disruption of transport phenomenon.

K•

Iyrngyer_gf_Brgteins_in_dystrgghic_animals
The intracellular process which regulates the mechanism

of protein turnover is a fundamental problem about which very
little is known (Katanuma et al., 1976). In skeletal muscle
the half-life of the proteins in the various muscles of adult
organism varies from 4—40 days depending on the source of the
muscle.
is

However, the turnover rate of the various proteins

dependent on a number of factors including age,

nutritional state, hormone balance and level of contractile
activity of the animal/musele under study (MilIward, 1980).
Unfortunately, numerous technical problems arise when one
attempts to measure protein turnover in skeletal muscle (and
other tissues) which make data assessment extremely difficult
(Everett and Zak, 1980).

Notwithstanding these difficulties.
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it appears certain that protein turnover in dystrophic muscle
of humans, mice, hamsters, chickens, and cultured dystrophic
cells is enhanced markedly compared with non-dystrophic
controls (Young and Munro, 1980; Garber et al., 1980b; Li,
1980; Ettienne et al., 1980). Moreover, since the outcome of
dystrophy is muscle wasting, there must be an accelerated rate
of protein degradation over protein synthesis in_yiyo.
The onset and progression of muscular dystrophy in humans
and animals is characterized by a marked increase in
intracellular protease activity in skeletal muscle, leading to
degradation of myofibrillar proteins, and muscle necrosis.
The proteases showing the greatest increase in activity in
dystrophic muscle are the thiol proteases, particularly
cathepsin B (Kar and Pearson, 1977).

Goldspink et al.(1977)

and Rouke (1975) have indicated increased proteolysis in
muscles in conditions such as muscular dystrophy and the
important role of lysosomal proteases in degradation of
myofibrilIs has been suggested by Weinstock and lodice
(1969).

Since increased lysosomal enzyme activities are found

in experimental myopathies and hereditary

muscular dystrophy,

these enzymes are frequently implicated as a major factor in
the muscle wasting process.

Consistent with this idea,

increased levels of cathepsin B have been observed in muscle
of patients with muscular dystrophy and related diseases (Kar
and Pearson, 1977; Katanuma et al., 1977).

Also, lysosomal

(thiol) proteases such as cathepsins B and L were found to
degrade purified myofibrillar proteins in_yi.trg

though in
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different ways (Schwartz and Bird, 1977; Noda et al., 1980;
Matsukura et al., 1981).

Given that the thiol proteases have

been shown to degrade a wide variety of sarcoplasmic and
myofibrillar proteins in_yi.tro, it would appear that control
of these enzymes in vivo is of vital importance in maintaining
normal cell function.
In recent years considerable attention has focused on the
physiological role of protease inhibitors in the process of
protein metabolism (Lasowski et al., 1980).

Since the time

Frankenstadt (1957) first reported the presence of endogenous
thiol protease inhibitors in rat liver, many workers have
attempted to purify and characterize these inhibitors.

The

inhibition of proteases by protein inhibitors is an intriguing
problem in studies of specific protein—protein interactions
(Ruhlman et al., 1973; Mitsui et al., 1979).

It has been

reported that several cathepsins of lysosomal origin which
play an important role in regulating the degradation of
soluble and structural proteins in many tissues have specific
endogenous inhibitors (Lenney, 1980).
proteinase inhibitors have

Several thiol

been isolated from mammalian

tissues (Udaka et al., 1965; Jarvinen, 1976; Lenney et al.,
1979; Kopitar et al., 1978; Hibino et al., 1980; Kominami et
al., 1982) which form reversible complexes either with a
specific

protease or its substrate.

Those which affect metal

containing proteases are usually larger proteins.

In most

tissues, these inhibitors are localised in the cytosol
fraction of the cell, whereas the majority of the proteases
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are associated with organe1les such as lysosomes, golgi or in
other particulate fractions (Lenney, 1980).

Furthermore,

three low molecular weight thiol protease inhibitors were
detected in human epidermis (Jarvinen, 1978).
(1980)

Hibino et al.

indicated that a protease inhibitor purified from new

born rat epidermis was synthesized in epidermal cells during
keratinization.

Ohitani et al. (1982) showed only subtle

differences in inhibitory activity between inhibitor from new
born rat and human epidermis towards several thiol proteases
despite significant differences in sequence homology.
Of relevance is the finding of Schwartz and Bird (1977)
who reported that rat muscle contains 2 inhibitors of
cathepsin B activity which can be inactivated by incubation of
muscle extracts at pH 4.5. These inhibitors have not been
fully character ised but they have molecular weights of 12,500
and 62,000 dal tons. It is presumed that the activity of
cathepsin B in muscle is regulated by these endogenous
inhibitors which are, in turn, regulated by hydrolases or some
other mechanism (Schwartz and Bird, 1977).

The importance of

proteinase inhibitors which suppress the activity of cathepsin
B and D and calcium activated neutral protease in normal
muscle, and which may be lost in diseased muscle, has been
suggested by the studies of Libby and Goldberg (1978) and
Stracher et al. (1978).

In this respect, the findings of

Spanier and Bird (1982) are most interesting. They have shown
that the gastronemius and masseter muscles from female guinea
pigs maintained on a vitamin E deficient diet have reduced
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cathepsin B inhibitor activity compared to similar cytosol
fractions prepared from guinea pigs on a normal diet.
Furthermore, they suggested that the apparent increase in
cathepsin B activity in muscle extract of vitamin E deficient
animals, and perhaps in dystrophic muscles, may be
attributable to a decreased level of endogenous protease
inhibitor in these groups of animals.

Of considerable

significance to the above findings are the results of Stracher
et al. (1978) who showed that leupeptin, an effective
inhibitor of cathepsin B and calcium activated neutral
protease, and pepstatin, an inhibitor of cathepsin D, inhibit
both the rate of total protein degradation and cathepsin B
activity in intact rat muscle in_yitrg.

Moreover, Libby and

Goldberg (1978) have reported that leupeptin and pepstatin are
able to offer some protection to the general architecture of
chick muscle and to reduce markedly the high level of serum
creatine kinase in dystrophic chicken when injections are
started one day after hatching. In other studies, Sher et al.
(1981)

have reported that leupept in treatment (via I.P.

injections) of 3 week old mice with genetic muscular dystrophy
delays the appearance of myopathy for at least 24 weeks.
Recently, Tsuji and Matsushita (1986) have reported successful
control of depeptidy1 peptidase activity in dystrophic mice
with the protease inhibitor bestatin along with the
disappearance of myopathological features characteristic of
the disease.

These studies, while incomplete, strongly

suggest that the loss of control of protease activity in
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skeletal muscle is of fundamental importance in the onset and
development of muscle wasting characteristic of various muscle
diseases.

While a potential role for protease inhibitors as

modulators of intracellular proteolysis has been recognised,
the intracellular function of the molecules involved are not
very well understood.

Since, the tissue proteins are subject

to continuous turnover, a control mechanism must exist to
ensure protein homeostasis and this control could also be
performed by protease inhibitors.

Thiol protease inhibitors

assayed for activity against cathepsin H have been found in
all organs of the rat (Kominami et al., 1982b).
Immunodiffusion analysis with anti-liver thiol protease
inhibitor serum indicated that the inhibitor in rat liver is
immunologically identical with the inhibitor in other rat
tissues (Kominami et al., 1982b). However, contrary results
have been reported recently where anti—rat liver inhibitor
serum did not react with anti-rat epidermis serum

(Katanuma

and Kominami, 1983). A comparison of the properties of the
purified inhibitors showed that at least two different types
of thiol proteinase inhibitors are present in the cell, the
liver type and the epidermal type. The presence of inhibitors
in various other tissues of mammals, including pigs, hamsters,
rabbits, and humans has been reported (Lenney et al., 1979;
Turk et al., 1982).

Thus intracellular protease inhibitors

seem to be ubiquitous in mammals.

However, species

specificity exists since, anti—rat protease inhibitor serum
did not cross react with either human or rabbit protease
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inhibitor (Wakamatsu et al., 1982).
Since the wasting of muscles in the various forms of
muscular dystrophy is obviously the consequence of breakdown
occuring at a rate exceeding that of resynthesis, a natural
approach to control this situation is to try and inhibit the
proteases responsible for the excessive degradation.

The

finding that muscle tissue extracts contain inhibitory
activity against thiol proteases (Schwartz and Bird, 1977)
prompted us to examine whether these inhibitors might be
involved in the modulation of protease activity in normal
muscle and whether changes,
occur in

if any, in inhibitor activity

dystrophic muscle which might be the cause for the

increased protease activity found in the diseased muscle.
This dissertation describes the purification and properties of
a thiol protease inhibitor from normal and dystrophic hindlimb
muscle of the mouse of strain 129/ReJ. This study, a part of
which has been published (Gopalan et al., 1986b) also shows
that the thiol protease inhibitor from dystrophic muscle is
functionally defective in the control of cathepsin B activity
compared with the thiol protease inhibitor protein from normal
mouse 1ittermates.
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II.

A.

MATERIALS AND METHODS

Animals
Dystrophic male mice (strain 129/ReJ-dy) and their normal

1ittermates were obtained from Jackson Laboratories (Bar
Harbor, Maine) at about 30 days of age and maintained in the
laboratory to age 60 days on standard laboratory chow
(Purina). Also, female mice of strain 129/ReJ, heterozygous
for the disease and normal retired breeders of the same strain
of about 9 months of age were used.

B.

Bigchemicals
N- (/- ben zoy1-DL-arg ini ne-2-naph thy1am ide (BANA),

N-oT-CBZ-L-arg iny1-L-arg inine-4-methoxy-B-naphthy1amide. Fast
Garnet GBC salt, azocaesin, rabbit myosin and pi markers for
isoelectric focusing
(St Louis, Mo.).

were purchased from Sigma Chemical Co

The protein molecular weight markers for

electrophoresis were from Pharmacia (Montreal, P. Q.).

The

Chemopack C-18 HPLC column was prepared by Dr. F. L. Huang
from material obtained from Chemco Scientific Co. (Osaka,
Japan).

Acetonitrile was of HPLC grade and the pi 3.5-10

ampholytes were from LKB (Fisher Scientific, Toronto, Ont.).
Ultrafi1tration Diaflo membranes were from Ami con Corp.
(Danvers, Ma.).

Aery1amide and SDS were from BioRad

Laboratories (Mississuaga, Ont.).

All other chemicals were of

reagent grade or better.
35
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c.

Methods

1•

Iissue_samEie_BreBaration
The tissues for isolation of thiol proteases and thiol

protease inhibitors (TPI’s) were obtained by cervical
dislocation of the animals and the tissues perfused in_situ by
pumping 40 ml of mammalian Ringers solution containing □.1 mM
EDTA through the animal at 20 ml per minute using direct
cardiac puncture.

The total hindlimb muscle and liver were

excised and used either immediately or stored at —70 C.

2.

Preparation_of_mouse_1iver_1ysgsoma1_thig 1_grg teases
Frozen livers from normal and dystrophic 60 day old male

mice were thawed, cut into small pieces and ground with fine
glass beads and 5 volumes of ice-cold 0.25 M sucrose in a
mortar and pestle at 4 C.

The homogenate was centrifuged at

600 X g for 10 minutes to remove intact cells and nuclei. The
resulting supernatant was centrifuged at 27,000 x g for 20
minutes to pellet the mitochondria and lysosomes (M+L).

The

crude M+L pellet was washed with about 25 volumes of 0.25 M
sucrose solution containing 0.1 mM EDTA and 0.03 M Tris-HCl,
pH 7.0, and the M+L fraction was collected again by
centrifugation as above.

The resulting M+L pellet was

suspended in 20mM sodium acetate, pH 5, containing 1 mM
dithiothreitoi (DTT), 0.1 mM EDTA and 10% glycerol and
homogenized thoroughly in a ground glass homogenizer.

The

homogenate was centrifuged at 27,000 x g and the resulting
pel let re-homogenized 3-4 times.

The 27,000 x g supernatant
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fractions were pooled and concentrated by ultrafi1tration on a
Diaflo YM-3 membrane and used as the source of lysosomal
(total) thiol proteases.

3.

Partial_Burifiçatign_gf_çatheBsins_B^_H_and_L_frgm_mguse
liver_lysgsgmes
Cathepsins B

(EC 3.4.22.1), H (EC 3.4.22.16) and L (EC

3.4.22.15) were prepared from the crude lysosomal extract from
mouse liver according to the procedure of Barrett and Kirschke
(1981) with slight modifications.

The total M + L

extract was

concentrated to about 2 ml by ultrafiltration as described
above and passed through a Sephadex G—75 column (1 x 50cm)
equilibrated with 20 mM sodium phosphate buffer pH 6,
containing 1 mM DTT and 0.1 mM EDTA and 10% glycerol.
fractions giving a positive reaction to N—

The

benzoy1—DL—

arginine—2—naphthylamide (BANA) as substrate were pooled and
concentrated on a Diaflo YM—5 membrane.
concentrate
X 19 cm)

The enzyme

was applied to a DEAE—cellulose column (DE—32, 1

equilibrated with 20 mM sodium phosphate, pH 6,

containing 1 mM DTT, 0.1 mM EDTA, and 10% glycerol.

The

column was washed with the equilibrating buffer and cathepsin
H (which does not bind to DEAE-cellulose) was collected in the
wash and concentrated by ultrafiltration (YM—5). Cathepsins B
and L were eluted from the column by stepwise elution with 0.2
M and 0.45 M NaCl, respectively, in the equilibrating buffer.
Each protease fraction collected from the column was pooled
and concentrated by ultrafiltration using a YM-3 filter.
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Cathepsins B, H and L prepared as above were used as test
thiol proteases in the inhibitor assays.

4.

Assay_fgr_cathegsins_B_and_H
The assay conditions for cathepsin B and H were the same

except that BANA was used as substrate for cathepsin H and
N—

CBZ— L—arg iny1—L—arg in ine—4—methoxy—naphthy1ami de was used

as the susbstrate for cathepsin B.

The reaction mixture

contained 0.05 ml of enzyme, 0.05 ml of incubation buffer
containing 0.074 M potassium phosphate,

1 mM EDTA and O.024%

cysteine (freshly prepared), and 0.05 ml of water.

The

reaction mix was incubated at 40 C for 5 min and then 0.010 ml
of BANA (40 mg/ml) or N-X“CBZ-L-arginyl-arginine-4-methoxynaphthy lami de (10 mg/ml) was added to start the reaction.
After O, 15, and 30 minutes, 0.05 ml of the reaction mixture
was removed into 0.025 ml of coupling reagent (pH 6.0)
containing 0.36% ch1oromercuribenzoate (PCMB) and 1.86% EDTA
in 0.05M NaOH, and kept on ice.

Color development occurred

upon addition of 0.025 ml of a fast garnet salt solution
(0.005% fast garnet in 4% BriJ 35).

Butanol was added to

extract the colored complex and the samples were centrifuged
in a clinical centrifuge to separate the phases.
phase was removed and analyzed at 520 nm.

The organic

One enzyme unit of

cathepsin B or H is defined as the liberation of 1 nmole of
naphthylamine per hour in a standard enzyme reaction mix.
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3.

Assau for cathepsin L
Azocaesin was used as substrate to determine the TPl

activity on cathepsin L according to the procedure of Barrett
and Kirschke (1981).

Azocaesin is a derivative of caesin in

which the tyrosine and histidine side chains have been coupled
with diazotized sulfani1ic acid or sulfanilamide in alkali.
The azo—coupling confers an intense yellow color on the
protein.

Proteolytic degradation of azocaesin yields peptides

soluble in dilute TCA solution, which may be quantified by
their absorbance at 366 nm.

The method is especially suited

for the determination of proteolytic activity in crude
samples, being very résistent to interference.
cathepsin L is made

The assay for

very specific by the inclusion of 3M urea

which enhances the activity of cathepsin L and depresses that
of cathepsin B.

Thus for the cathepsin L assay, 0.25 ml of

enzyme preparation was mixed with O.25 ml of an assay buffer
containing 0.1 M sodium acetate, pH 5, and 1 mti EDTA and 40 mM
cysteine (freshly prepared).

After 5 minutes at room

temperature, 0.3 ml of an azocaesin-urea mixture (10 ml of 6%
azocaesin and 10.8 g of urea in a final volume of 30 ml assay
buffer lacking cysteine) was added.
minutes,

After O, 15, and 30

1 ml of 3% TCA was added to the reaction vessels and

the mixture centrifuged in a clinical centrifuge.
supernatant was removed and analyzed at 366 nm.

The
One enzyme

unit of cathepsin L is defined as the amount of enzyme which
brings about a change of 0.01 A^66

minute.
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6-

Assay s_gf _ th ig l^gr g teasg_ iniîib itor _aç t iy ity
Determination of thiol protease inhibitor (TPI) activity

during the purification procedure was carried out using the
crude M+L extract as described above as the source of the
total lysosomal thiol proteases.

N—

— benzoyl—DL—arginine —

2—naphthylamide (BANA) was used as the substrate.

The extent

of 2—naphthylamine liberation from BANA by thiol proteases, in
the presence of various column fractions (see purification of
inhibitor in Results), was measured using the procedure of
Barrett (1972).

Each reaction vessel contained 0.075 M

potassium phosphate, pH 6, 1 mM EDTA, O.024% cysteine,

1 mg/ml

BANA, 40-50 milliunits of thiol protease activity, and 0.1 ml
of various column fractions in 0.8 ml total volume.

Aliquots

of 0.25 ml were removed after an appropriate incubation period
at 40 C (usually 30 minutes), and the percent inhibition of
2-naphthylamine liberation was determined.
The inhibitor activity in each TPI preparation was
measured using papain (EC 3.4.4.10) and cathepsins B, H and L
as test proteases.

With papain or cathepsins B as the test

protease, the substrate was

N—

JL—

CBZ-L-arg in y 1—arg ini ne—

4-methoxy-naphthylamide while with cathepsin H the substrate
was BANA.

Azocaesin was the substrate for cathepsin L. One

inhibitor unit is defined as the amount of protein required to
reduce the thiol protease activity by one enzyme unit.

7.

Purity_and_mglecular_weight_determinatigns_gf_the_TPlls
The purity and molecular weight of the TPI from normal and
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dystrophic mouse muscle were analyzed on 7 18% gradients of
polyaery1ami de gels (1.5 x 100 x 135 m m ) containing 0.1%
sodium dodecyl sulfate (SDS) according to the procedure of
Laemmli (1970).

Protein was stained with Coomassie brilliant

blue (R-250) in 7.5% acetic acid and 50% methanol, and the gel
destained in a solution composed of 7.5% acetic acid and 5%
methanol.

The molecular weight of the TPI’s was determined

using the following standard molecular weight markers:
phosphorylase b (Mr 94,000), bovine serum albumin (Mr 67,000),
ovalbumin (Mr 43,000), carbonic anhydrase (Mr 30,000), soybean
trypsin inhibitor (Mr 20,100) and /-lactalbumin (Mr 14,400).

8.

Analysis_gf_IPIls_gn_isoeleçtriç_foçusing_gels
Isoelectric focusing of the purified TPI’s was carried out

in Jacketed glass columns (4 x 100 mm) containing 6%
polyacrylamide gels with 2%of 3.5— 10
the procedure of Blerkom (1970).

ampholytes according to

Electrophoresis was carried

out for at least 6 hours at 75 volts and 0.5 ma per column. At
the end of the run, one gel from each set was cut into 2 mm
sections, and each section was placed in a vial containing 1.2
ml of nanopure water. The vials were covered with parafilm and
after three to four hours at room temperature, the pH of each
gel extract was measured using a micro-pH electrode.

A second

gel was washed in ice-cold water overnight with at least 4
changes of fresh cold water,

and then cut into 2 mm sections,

and each section was placed

in a vial containing 0.5 ml of 50

mM Tris-HCl and 0.2 M NaCl, pH 8.

After incubation at 40 C
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for 30 minutes, the amount of thiol protease inhibitor in each
gel extract was determined using either papain or cathepsin B
as test protease as described above.

A third gel was placed

in 5% TCA for 3 hours and subsequently stained for protein
with Coomassie blue

as described above for the

SDS—polyacrylamide gels. In some experiments standard proteins
with known pi values were run along with the TPI’s to provide
an additional means of assessing the pi values of the TPI’s.
The standard protein mix for the latter assay contained
amyloglucosidase (pi 3.53), methyl red (pi 3.73), soybean
trypsin inhibitor (pi 4.55), p-lactoglobulin A (pi 5.13),
carbonic anhydrase (pi 5.85), myoglobin (pi 7.16 and 6.76),
and L-lactic dehydrogenase (pi 8.55).

9•

High_Berfgrmançe_liguid_çhrgmatggraghy_gf_TPIls
Thiol protease inhibitor from normal and dystrophic muscle

was analyzed on a C-18 reverse phase column (4.6 x 250 mm,
Chemopack) driven by a Gilson HPLC system.
equilibrated with 12% acetonitrile

The column was

containing G.1%

trifluoroacetic acid (TFA), and following sample injection,
the protein was eluted at a flow rate of 1 ml/min using a
linear gradient (40 minutes) of acetonitrile to 60% with 0.1%
TFA.

The column effluent was monitored at 214 nm using a

Gilson Holochrome detector.
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10.

Assay_fgr_mygsin_bUdrglysis_by_çatheBsin_B_in_the_

gresence_gf_TPl3 Q_and_TPIzd
The effect of TPI-n and TPI-d on the hydrolysis of rabbit
myosin was analyzed on a 7-18% SDS-polyacrylamide gel as
described above.

Reaction vessels containing 20 mM sodium

acetate pH 5, 1 mM EDTA, 1 mM DTT, 0.15 M KCl, 10 % glycerol,
rabbit myosin 0 8 >ig), cathepsin B (16.8 mi 11 i-units) , and
TPI-n (46 >ig) or TPI-d (46 >ig) in separate reaction vessels
were incubated at 40 C for periods up to 1 hour.

The

reactions were stopped at the desired time by heating an
aliquot of the reaction mixture at 95 C for 5 minutes in the
presence of 1 % SDS.

Samples were then applied to an

SDS—polyacrylamide gel slab and electrophoresed at 130 volts
for 3 hours.

11. Thymgl_sulfuric_açid_test_fgr_glyçggrgteins
The presence of glycoprotein in the TPI-n and TPI—d
preparations was tested using the thymol—sulpfuric acid method
outlined by Gander (1984).

After electrophoresis the gels

were washed with isopropanol—acetic acid-water (25:10:65) for
at least 2 hours to fix the proteins and to remove the low
molecular weight substances.

After two additional washes the

final wash was done for another 2 hours in the same solvent
containing 0.2% thymol (w/v).

After washing with thymol, the

gel was transferred to a solution of concentrated sulfuric
acid and absolute ethanol (80:20) and shaken at room
temperature for a minimum of 2 hours or until the opalascent
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appearance of the gels Just disappeared. Zones containing
glycoproteins stained red, whereas the background remained
yellow.

Proteins lacking carbohydrate markers do not form red

bands when treated in this manner.
The normal and dystrophic inhibitor proteins were run on
a 7— 18% SDS—polyacrylamide gel and stained for glycoproteins
using an acid protease from Artemia embryos, a known
glycoprotein, as a marker.

12.

Protein_determlnation
The protein content of each enzyme and inhibitor

preparation was

determined by the method of Lowry et

al.(1951) using bovine serum albumin as protein standard.
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III.

RESULTS

A. Purificatign_of_a_thiol_BrgteasG_inhibitgr_frgm_ngrmal_and
dystrgghic_mguse_muscle
The low molecular weight thiol protease inhibitors from
60 day old normal (TPI—n) and dystrophic (TPI—d) mouse
hindlimb muscle were purified to apparent homogeneity as
described by Hirado et al. (1981) with slight modification.
Approximately 4—5 grams of hindlimb muscle from 3 normal or 6
dystrophic mice were homogenised thoroughly with 5 volumes of
10 mM Tris-HCl, pH 8.0 containing 1 mM dithiothreitoi, 0.2 M
NaCl and 10% glycerol in a loose fitting ground—glass
homogenizer.

In each case the homogenate was centrifuged at

27,000 X g for 20 minutes and the supernatant fluid passed
through miracloth to remove any floating material.

The

filtrate was adjusted to pH 5.0 with acetic acid and then
stirred for 3-4 hours at 4 C.

The precipitate that formed at

pH 5 was removed by centrifugation and the crude extract was
concentrated to about 2 ml by ultrafiltration using a Diaflo
YM—5 (Amicon) membrane.
After concentration, the crude extracts from normal and
dystrophic muscle were applied (separately) to a Sephadex G—50
column (1 X 50 cm, superfine) equilibrated with the
homogenization buffer, and the protein was eluted with the
same buffer.

Each column fraction was assayed for UV

absorbing material at 280 nm and for TPI activity using a

45
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crude thiol protease preparation front normal mouse liver and
benzoyl arginine naphthylamide (BANA) as substrate at pH 6.
The column fractions containing inhibitor activity were pooled
and concentrated by ultrafiltration using a Diaflo YM—2
(Amicon) membrane.
The concentrated TPI preparation from the Sephadex G-50
column was applied to a Sephadex G—75 column (1 x 50 cm,
superfine) equilibrated with homogenization buffer, and the
protein was eluted and analyzed as described above for the
first gel filtration step.

The column fractions containing

inhibitor activity were pooled and concentrated by
ultrafiltration on a Diaflo YC—05 (Amicon) membrane.

The TPI

preparation was rechromatographed on a second Sephadex G—75
column and fractions containing inhibitor activity were pooled
and concentrated as before.

The final préparâtions,

designated as TPI-n from normal mouse muscle and TPI-d from
dystrophic mouse muscle were stored at —20 C.
The results in Figure 2 show the elution and activity
profiles of the TPI’s after each chromatographic step.

The

protein content and inhibitor activity after each step in the
purification process are also summarized in Table 1.
aspects of the data in Table 1 are notable.

First,

Two
it is

clear that crude extracts of dystrophic muscle contain about
75% less inhibitor activity than crude extracts from normal
muscle, data which are consistent with that reported
previously from this laboratory (Gopalan et al., 1986a).
Since I did not attempt to inactivate the thiol protease
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Figure 2-

Purification of TPI-n and TPI-d on gel filtration
columns.

All columns (1 x 50 cm)

were

equilibrated with buffer containing 10 mM Tris-HCl,
pH By 0.2 M NaCl, 1 mM DTT and 10% glycerol.

The

protein was eluted with the same buffer.

Panel A:

Crude extract from hindlimb of normal
mice on Sephadex G—50 (superfine) column

B:

TPI-n activity on the first Sephadex G—75
(superfine) column from pool of Sephadex
G-r50 column material (A).

C:

TPI-n activity on second Sephadex G-75
(superfine) column from pooled material
from the first Sepahdex G—75 column (B)

D:

Crude extract from hindlimb of dystrophic
mice on Sephadex G—50 (superfine) column.

E:

TPI-d activity on the first Sephadex G-75
(superfine column) from pool of Sephadex
G—50 column (D).

F:

TPI-d activity on the second Sephadex
G-75 (superfine) column from pooled
material from the first Sephadex G-75
column (E).

O---0, protein as measured by absorbance at A2b o *
X--- X, inhibitor activity (as percent inhibition)

using total lysosomal thiol proteases with
BANA as substrate.
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Table 1.

Summar U_Qf _s tees_ i.n_ the_gur if iça tign _g f_th ig l._Brg tease
i!ïbibitgr_frgm_ngrmai_and_dystrgghiç_mguse_musçle^

Fract ion^

Total Protein
(mg)

Total
milli-IU

Specific
Act ivi ty

Normal muscle"
Crude extract

36.6

760

21

Sephadex G-50

32.3

1160

36

1st
Sephadex G—75

5.6

1388

248

2nd
Sephadex G—75

2.4

1203

501

Dystrophic

muscle^

Crude extract

43.8

198

5

Sephadex G—50

20.8

1285

62

1st
Sephadex G-75

3. 7

1012

274

2nd
Sephadex G—75

2.7

891

330

^ Each preparation was assayed using 41 milliunits of thiol
protease activity in a standard reaction vessel.
*^4.5 grams of muscle were taken from normal mice and
4.6 grams were taken from dystrophic mice.
The data presented in this Table are représentâtive of one of 15
experiments conducted.
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activity in the crude extracts, it is likely that the low
inhibitor levels in these preparations are due to elevated
amounts of these enzymes which lower the apparent inhibitor
activity (Ohtani et. al., 1982).

Second, the total TPI

activity in the final preparation (after the 2nd Sephadex G-75
step) is about 35% higher in preparations from normal muscle
than from dystrophic muscle.

These differences are not

significant for reasons described below.
In several other preliminary experiments, attempts to
purify the protease inhibitor on CM—cellulose, DEAE-cellulose,
CM-affigel blue, agarose blue, papain sepharose, and Con-A
sepharose columns were made..

In all of these cases

unsatisfactory yields of activity were obtained (compared with
the gel filtration protocol used here) so further attempts to
use these media to purify the inhibitor were abandoned.

B. Physical_BrgBerties_gf_the_thigl_grgtease_inhibitgr_frgm
DQrmal_and_dystrgBhic_hindlimb_muscle_gf_the_mguse
Selected physical properties of TPI-n and TPI-d
Preparations after the second Sephadex G-75 column were
analyzed using three analytical procedures:

SDS-polyacry1-

amide gel electrophoresis, high performance liquid
chromatography, and analytical isoelectric focusing.

The

migration property of the protein in each TPI preparation on a
7—18% gradient of polyacrylamide in the presence of O.1% SDS
is shown in Figure 3.

These data show that only one

polypeptide is present in each inhibitor preparation, and
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Figure 3.

Comparison of TPI—n and TPI—d after SDS—polyacryI—
amide gel electrophoresis.

Samples of each thiol

protease inhibitor preparation, after the second
Sephadex G—75 step were electrophoresed on a 7— 18%
polyacrylamide gel in the presence of 0.1% SDS.
Lanes 1 and 4 are standard molecular weight
proteins.

Lane 2 contains 20 jig TPI-n while lane 3

contains 20 jig TPI-d.
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based on migration distances of the TPI’s compared with
standard protein markers, the molecular weight of each TPI was
calculated to be 14,800.
Figure 4.

The latter results are shown in

The results in Figure 5 compare the elution

P>“ofiles of TPI-n and TPI-d from an HPLC column (4.6 x 250 mm,
Chemopack).

The column was eluted with a linear gradient (40

minutes) of acetonitrile to 60% containing 0.1% TFA.

Only one

major protein peak was detected in each preparation.

TPI—n

and TPI-d also co—eluted from the HPLC column when present as
s mixture (data not shown).

Both TPI—n and TPI-d eluted from

^he HPLC column at 47% acetonitrile.
Data from the analytical isoelectric focusing experiments
shown in Figure 6.

The only protein detectable on these

Gels after staining with Coomassie brilliant blue focused at
pH 4.5.

Mixtures of TPI-n and TPI—d also gave a single band

Upon focusing at pH 4.5. These data show that both TPI-n and
d are apparently homogeneous after the second Sephadex
®~75 step and that they have very similar, if not identical,
physical properties.

^• Ô Ç tivitu_gf_IPi-n_and_IPi-d_gn_varigus_thiol_ergteases

The inhibitor activity of purified TPI-n and TPI-d was
compared using papain and cathepsins B, H and L and the
'Results are shown in Figure 7. When both TPI’s were tested
^gainst papain, no differences in inhibitor activity were
found, and both TPI’s inhibited papain by 50% (ID^g) at 4
.

With normal mouse liver cathepsin B, TPI-d was
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Figure 4.

Molecular weight determination of the thiol
protease inhibitor protein-

Standard protein

markers used were phosphory1ase b (94,000), bovine
serum albumin (67,000), ovalbumin (43,000),
carbonic anhydrase (30,000) soybean trypsin
inhibitor (20,100), and oC-lactalbumin (14,400).
The arrow indicates the electrophoretic position of
TPI-n on the gel compared to the standard proteins.
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Figure 5.

High performance liquid chromatography of TPI—n and
TPI—d.

Samples of TPI-n (10 >ag) and TPI-d (5 ^ g )

were applied in separate runs to a C-18 reverse
phase column (Chemopack, 4.6 x 250 mm) previously
equilibrated with 12% acetonitrile containing 0.1%
TFA.

The columns were developed with a linear

gradient (over 40 min duration) of acetonitrile to
60% containing 0.1% TFA-

The actual tracing from

the recorder is shown here including the column
pressure curve (p) and zero voltage curve (v).

The

small vertical arrows indicate material present in
the buffer as observed in a separate run (not
shown).
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Figure 6.

Isoelectric focusing gels containing TPI-n and
TPI-d and a mixture of TPI-n and TPI-d.

The pi

of the standard proteins are shown at the far
left.
Lane 1. Standard protein mix together with TPI-n
+TPI-d.
Lane 2. TPI-n

only (20 jag).

Lane 3, TPI-d

only (20 jag).

Lane 4. TPI-n

+ TPI-d (40 jag total)-

The standard proteins used were:

L—Lactic

dehydrogenase (pi 8.55), myoglobin (pi 7.16 and
6.76), carbonic anhydrase (5.75), p— lactoglobulin
A (pi 5.13), methyl red (3.75) and amyloglucosidase
(pi 3.55).
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Figure 7,

Effect of TPI—n and TPI— d on the activity of
various thiol proteases.

Varying amounts of

inhibitor from normal (N) and dystrophic (D) muscle
were added to a standard reaction vessel containing
one of the thiol proteases indicated, and the
percent inhibition was determined.
X ---- X, indicates TPI from normal muscle.
8 -----

indicates TPI from dystrophic muscle.

Cathepsins B, H and L were from normal mouse liver»
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inactive while TPI-n had an IDgg of 7.5 jjg/ml.

No

significant differences in inhibitor activity were observed
using cathepsin L, while with cathepsin H about 35% more TPI—d
was required to reach the IDgg level.

Similar findings were

observed using cathepsin B, H and L isolated from livers of
dystrophic mice.

These findings are summarized in Table 2.

Thus while the thiol protease inhibitor from normal mouse
muscle (TPI—n) appears to be effective in the regulation of
papain and homologous cathepsins B, H and L, the thiol
protease inhibitor from dystrophic mouse muscle (TPI-d)
appears to be inactive against cathepsin B, partially active
when cathepsin H is used, and fully active when cathepsin L
and papain are the test enzymes.

The fact that TPI—d

preparations are unable to regulate cathepsin B activity under
Conditions (in vitro) where TPI—n preparations are active is
an important observation.

0• ActiVity_of_IPI-n_and_IPI-d_after_isoe1ectric_fOÇUSing_gn
BQiuacrylamide_gels
To ascertain whether the inhibitor activity in each
preparation is associated with the major protein observed on
SDS-po1yaery1amide and isoelectric focusing gels,

10-20 ;jg of

each TPI preparation were electrophoresed on analytical
isoelectric focusing gel columns, either separately or as a
mixture.

One gel was left intact and analyzed for protein by

staining with Coomassie brilliant blue (R—250), while the
other gels were cut into 2 mm sections.

One of the latter was
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used to determine the pH gradient that formed during the
electrophoretic run.

From the other cut gels, protein was

eluted with 30 mM Tris—MCI containing Ü.2 M NaCl, pH 8.

In

one of these gels, protein from each section was extracted and
assayed for inhibitor activity against papain, while in the
other gel, extracts of sections were assayed for inhibitor
activity against cathepsin B.

Results of these experiments

are shown in Figure 8.
As observed previously (see Figure 6), only one discrete
protein band could be detected in either TPI—n or TPI—d
préparât ions.

The pH at which this protein focused (pl) was

determined to be 4.5 by direct pH measurements of individual
gel sections (as shown in Figure 8), and by the use of protein
standards with known pi values as shown in Figure 9.

Assays

of protein eluted from the gel sections revealed that while
the TPI—n of pi 4.5 is active against both papain and
cathepsin B, the pi 4.5 protein in the TPI—d preparation is
inactive against both of these proteases.

However, the agent

in the TPI—d preparation which inhibited papain in other
experiments (see Figure 7) focused at pH 4.9.

This inhibitor

could not be detected with Coomassie blue stain, and it was
clearly different from the major protein which focused at pH
4.5,

When equal amounts of TPI—n and TPI—d preparations were

combined, electrophoresed on an analytical isoelectric
focusing gel column, and then analyzed for inhibitor activity
as before, both inhibitor activities were detectable using
papain as the test thiol protease (see Figure 8c).

These
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Figure 8.

Analysis of TPI—n and TPI— d on analytical
isoelectric focusing gels.

Samples containing

either TPI—n (20 jjg), TPI—d (20 jag) or a mixture of
both (TPI-n + TPI-d, 40 jag) were run on analytical
isoelectric focusing gels, then analysed for
protease activity using either papain (panel A, Bj
C) or cathepsin B (panel D, E, and F) as test
proteases.

The photograph at the top of each panel

shows the Coomassie blue stained protein in gels
run in parallel compared to the pH gradient (--- )
and inhibitor activity in separate gels containing
TPI-n (X --- x) and TPI-d (1

#) or a mixture

inhibitor proteins.
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Figure 9.

Determination of pi values of the thiol protease
inhibitor protein.

Standard proteins with known pi

values were run with normal mouse muscle TPI as
shown in Figure 6.
Standard proteins used were

1)lactic dehydrogenase

(pi 8.55), 2 and 2a) myoglobin (pi 7.16 and 6.76),
3) carbonic anhydrase (pi 5.85), 4) lactoglobulin
(pi 5.13), 5) methyl red (pi 3.75), and
6 ) amyloglucosidase (pi 3.55).

The arrow

indicates the position of the inhibitor protein in
the gel.
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results demonstrate that the TPI— d protein which focuses at pH
4.5 lacks inhibitor activity using either papain or cathepsin
B as the test protease.

Otherwise it is identical to TPI-n

which is active on papain and cathepsin B.

The inhibitory

activity in the TPI-d preparations must be due to some other
substance, either a protein in amounts too small to be
detected by staining with Coomassie blue, or some other
component.

E . Effect_gf_TPI-n_and_TPIzd_gn_the_hydrglysis_gf_mygsin_by
Çathegsin_B
It had been demonstrated previously that cathepsin B
hydrolyzes myofibrillar proteins (Schwartz and Bird,

1977),

Therefore, the efficiency of TPI-n and TPI-d in blocking the
hydrolysis of myosin by cathepsin B was examined in_y^trg.
Rabbit myosin was incubated with mouse liver cathepsin B and
TPI-n or TPI—d in separate reaction vessels.

After incubation

for one hour at pH 5 and 37 C, the reaction products were
analyzed by electrophoresis on a 7-18% polyacrylamide gel in
the presence of 0.1% SDS.
shown in Figure 10.

The results of this experiment are

From these data it is clear that TPI—d is

unable to prevent the hydrolysis of myosin by cathepsin B in
contrast to TPI-n (compare columns 6 and 7 in Fig 10).

The

arrow in Fig lO indicates the position of TPI—n and TPI-d.
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Figure 10.

Effect of TPI-n and TPI-d on myosin hydrolysis by
cathepsin B-

Reaction vessels containing rabbit

myosin (38 jjg), partially purified cathepsin B
(16.8 milli—units), and different thiol protease
inhibitors (46 jjg of each) in a reaction volume of
115 ul were set up and incubated as shown below.
Aliquots (40jjil) of each reaction were analysed on
7— 18% polyacrylamide gel slab.
Lane 1.

myosin only 60 min. 37 C.

Lane 2.

myosin + cathepsin B, 5 min. 37 C.

Lane 3.

myosin + cathepsin B + TPI—d, O min. 37

Lane 4.

myosin + cathepsin B + TPI-n, O min. 37 C

Lane 5.

myosin + cathepsin B, 60 min. 37 C.

Lane 6.

myosin + cathepsin B + TPI-d, 60 min. 37C

Lane 7.

myosin + cathepsin B + TPI-n, 60 min.

37 C

The protein band identified by the arrow at the
right is the TPI protein.
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F . p H and thermal atabilitu of TPI-n
The stability of TPI-n at different pH was studied using
cathepsin B as the test protease.

When the protein was

incubated for 1 hour in buffers at pH values ranging between
3— 10 (20 mM sodium acetate for pH range 3—5, and 20 mM sodium
phosphate for the pH range 6— 10) for 1 hour and then assayed
at pH 6, the results shown in (Figure 11) were obtained.
These results show that the normal muscle protease inhibitor
(TPI—n ) is most stable at pH 6 and is inactive below pH 5 or
above pH 8.0.
To determine the stability of the normal protease
inhibitor at different temperatures, purified TPI-n was
incubated at varying temperatures ranging from 30 C to 95 C
for 1 hour at pH 6. The inhibitor activity remaining after
heat treatment was examined using cathepsin B as the test
protease in the standard reaction vessel. The results of this
experiment are presented in Figure 12 and show that the
inhibitor activity (TPI—n) is stable at temperatures up to 65
C and inactivated above this temperature. Similar observations
on pH and thermal stability have been made using rat epidermal
thiol protease inhibitor by Takeda et al., 1983.

G" Effeçt_gf_trygsin_treatment_gn_TPI%n
The effect of trypsin on TPI—n activity was determined by
preincubating 12 units of normal thiol protease inhibitor for
2 hours with 10 and 20 units of trypsin in separate reaction
Vessels.

After the incubation period, 10 and 20 units of

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

73

Figure 11.

Stability of TPI—n at various pH.

Purified TPI-n

was incubated at various pH ranging from 3— 10 for
1 hour at 40 C, and then assayed for inhibitor
activity against cathepsin B at pH 6.0 as
described in the Methods.
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Figure 12.

Thermal stability of TPI-n.

Purified TPI-n was

incubated at varying temperatures ranging from
30 to 95 C for 1 hour at pH 6.

The

inhibitor activity remaining after the heat
treatment was measured using cathepsin B as the
test protease.
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soybean trypsin inhibitor were added to the reaction vessels
to counteract the trypsin, and the remaining thiol protease
inhibitor activity (if any) was assayed using cathepsin B as
the test enzyme.

Under these conditions no inhibitor activity

was lost by the trypsin treatment compared to the control
samples not treated with trypsin. Samples from similar
reactions were analyzed using SDS—po1yaery1amide gel
electrophoresis and high performance liquid chromatography and
the treated TPI-n was found to be unchanged (data not shown).
These results show that normal mouse muscle thiol protease
inhibitor is resistant to trypsin digestion and, in this
respect, is similar to rat skin epidermal protease inhibitor
(Takio et al., 1984).

H . Purification of TPIs from carrier m ice heterozuaous (+/dy)
for muscular dustrophu and disease free normal retiyed
breeders_l±/±l
The low molecular weight thiol protease inhibitor from
carrier females (TPI—h) heterozygous for the disease, and
disease free retired females (TPI-c) (both approximately 9
months of age) was isolated using the same procedure as for
the normal or dystrophic hindlimb muscle of younger mice.

The

f'esults in Table 3 show the amount of thiol protease inhibitor
activity in hindlimb muscle of heterozygous (+/dy) and disease
free retired breeder mice (+/+) compared to the protease
inhibitor activity in normal and dystrophic young males (2
months old).

From these results it is clear that there is
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Ç g n t e n t _ a n d _ i n h i b i t g r _ a ç t ^ y i,t y _ g f _ T P 1 3 h _ a n d _ T P I - ç _
iD_bindlimb_musçle_çgmgared_with_TPI%n_and_TPI-d

Source of muscle
inhibi tor

Total protein

Total inhibitor

Speci f ic

content

activity

act ivi ty

(mg )

(milli-units)

(units /mg
protein)

Normal males
(2 months old)

2.4

1203

501

2.7

891

330

3.4

2784

568

6.2

4862

788

Dystrophic males
(2 months old)

Carrier females
(9 months old)

Normal breeders
(9 months old)

The above values were obtained from 5 grams wet weight of
h indlimb.
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3 to A fold more thiol protease inhibitor in the normal
retired females than in the normal young males. The content of
protease inhibitor in carrier females, heterozygous for the
disease (+/dy), also showed more inhibitor activity than
young dystrophic males, but less activity than normal, age
matched females. These data suggest that the inhibitor
concentration in mouse muscle increases with age.

^• Obysical_firoBerties_of_IPlzh_and_TPI-c
The TPI-h and TPI-c preparations after the second
Sephadex G—73 column were analysed using SDS-polyacrylamide
gel electrophoresis, isoelectric focusing and high performance
liquid chromatography.

The migration properties of TPI—h and

TPI—c during electrophoresis on a 7— 18% gradient of
polyacrylamide in the presence of 0.1% SDS show that only one
polypeptide is present in each inhibitor preparation.

Based

on the migration distance of the TPI*s compared to standard
P*"otein markers, the molecular weight was determined to be
14,800 which is the same as that for TPI—n and TPI-d.

The

Glut ion profile of TPI—h and TPI-c from an HPLC column is
shown in Figure 13.

Only one major protein peak was detected

in each preparation, and this protein eluted at the same
position as TPI-n and TPI—d (see Figure 5 also).

• Effeçt_gf_TPI-h_and_TPI-ç_gn_çathegsins_Bj^_H_and_L_and
gagain
Effect of TPI—h and TPI-c on mouse liver cathepsin B, H
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Figure 13.

Chromatography of TPI-c and TPI-h on HPLC
column.

lOO jig of the TPI-h and TPI-c were

applied separately to a C— IS reverse phase column
(Chemopack, 4.6 x 250 mm) equilibrated with 12%
acetonitrile and 0.1% TFA.

The protein was eluted

from the column with an acetonitrile gradient as
described in the legend to Figure 5.

The actual

tracing from the recorder is shown here including
the column pressure curve (p) and zero voltage
curve (V ).
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and L and papain was tested exactly as for TPI—n and TPI—d
(see Fig. 7 and Table 2).

Figure 14 shows the results of

these experiments and Table 4 shows the IDgg values of TPI—h
and TPI-c for the different enzymes.

In all cases the IDgg

data were found to be similar to that obtained for TPI-n
(compare with data in Table 2).

K - Analysis_gf_TPI=h_and_TPI%ç_gn_isgeleçtriç_fgçusing_gels
To ascertain whether the inhibitor activity is associated
with the major protein on SDS-po1yacry1amide and isoelectric
focusing gels, 50 jag of TPI-h and TPI-c were electrophoresed
separately on gel columns and the columns were then analyzed
for pH, protein content and inhibitor activity as before.
With both TPI-h and TPI— c only one discrete protein band
could be detected and these results are shown in Figure 15.
The pH at which the inhibitor protein focused was 4.5.

Assays

of the inhibitor activity in the protein extracted from the
gels showed that, in both cases, the protein which focused at
pH 4.5 was active against cathepsin B.

However,

in the TPI—h

preparation, apart from the peak of inhibitor activity at pH
4.5, inhibitor activity was also observed at pH 4.9 when
papain was used as the test enzyme.

This inhibitory agent,

whatever its nature, appears to be the same component observed
previously in muscle TPI—d preparations (see Fig. 8).

Again,

as with the protease inhibitor from dystrophic muscle, the
inhibitor activity which focused at pH 4.9 could not be
stained with Coomassie brilliant blue.

TPI—c showed only one
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Figure 14.

Effect of TPI— c and TPI—h on papain, and
cathepsins B, H and L.

Varying amounts of

inhibitor protein from carrier females (TPI-h) and
normal female breeders (TPI— c) were added to
separate standard reaction vessels containing the
thiol proteases as indicated and the percent
inhibition was determined.
#--- #,

TPI— c from normal female breeders.

X---- X,

TPI-h from carrier females.
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Figure 15.

Isoelectric focusing of TPI— c and TPI— h on a
polyacrylamide gel support.
Samples containing TPI— h (50 jag) or TPI— c (50 jag)
were run on analytical isoelectric focusing gels
and then analysed for protease inhibitor activity
using papain (panel A and B) and cathepsin B
(panel C and D) as test proteases.

The

photographs at the top of each panel show the
Coomassie blue stained protein in a gel run in
parallel compared with the pH gradient (.— .) and
inhibitor activity in separate gels containing
TPI— c (O —

Note:

O) and TPI— h (x—

x ).

The photographs at the top each panel were

trimmed on either side because they were 10%
longer than the gel length as shown in the diagraM*
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peak of activity, and this material coincided with the protein
band at pH 4.5.
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IV. DISCUSSION
It has long been established that the onset and
progression of muscular dystrophy is associated with increased
activity levels of several proteases, but there has been
little agreement among researchers in the field as to the
biochemical lesion(s)

responsible for the onset of the

disease in mammals (Ayogi et al., 1981; Wada et al., 1981;
Perry, 1984; Sweeny and Brown, 1981).

One of the theories as

to the cause of the disease is that proteases are responsible
for the cytoarchitectural lesions since an increase in
protease activity has been noticed in dystrophic muscles of
numerous animals including chickens (Ettienne et al., 1980),
mice (Garber et al., 1980a), hamsters (Li, 1980) and humans
(Kar and Pearson, 1976).

A con comm iten t

increase in protease

inhibitor activity has been reported in many tissues of
diseased animals (Lenny, 1980), but the exact nature and
source of these inhibitors has not been established.
In an earlier study we demonstrated that crude extracts
from dystrophic mouse muscle (strain 129 ReJ/dy) contain a
greater proportion of active to inactive thiol protease
activity than crude extracts from normal muscle (Warner et
al., 1983; Gopalan et al., 1986a).

We suggested that enhanced

thiol protease activity in dystrophic muscle could result from
a lesion in one of the protease regulatory mechanisms which
normally masks over 80% of thiol protease activity in skeletal
89

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

90

muscle.

Such a defect could account for the 4—6 fold increase

in thiol protease activity observed in crude extracts of
skeletal muscle in most dystrophic animals.
In the study presented here, a purification procedure
based mainly on gel filtration columns and one which avoids a
heat step, common1y used by other researchers was used.

Since

the latter procedure often gives rise to multiple molecular
forms of inhibitor activity (Katanuma et al., 1983a).
Ion—exchange and papain—sepharose affinity columns were not
used in the purification protocol as established for TPI
purification by other researchers because considerable
inhibitor activity was lost using these media. It is also
known that papain-sepharose affinity columns generate
artifacts if not used carefully (Lenney et al., 1979; Hirado
et al., 1981 ; Katanuma et al., 1983a).

Also, since it is

known that some low molecular weight thiol protease inhibitors
are inactive in the absence of sulfhydry1 agents, all buffers
contained 1 mM DTT to minimize oxidation of thiol groups (if
present) in the proteins (Kominami et al., 1982a).

Thus by

using only gel filtration chromatography, a thiol protease
inhibitor protein has been obtained from the hindlimb muscle
of dystrophic (TPI—d) and normal (TPI—n) males, carrier
females heterozygous for the disease (TPI-h) and normal
retired females (TPI—c).

In all cases the purified protease

inhibitor appears to be homogeneous by three criteria:
SDS—polyacrylamide gel electrophoresis (Fig. 3), isoelectric
focusing

(Fig 6, 15) and high performance liquid
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chromoatography (Fig 3, 13). Furthermore, the inhibitor from
normal muscle (TPI—n), carrier females (TPI-h) and normal
females (TPI—c) all have an IDgg (6—9 ug/ml) similar to low
molecular weight thiol protease inhibitors from other mammals
(Hirado et al., 1981; Kominami et al., 1982a).

The major

difference between the thiol protease inhibitor from normal
and dystrophic muscle of the mouse is that TPI-n is active in
the regulation of cathepsin B activity, while TPI—d is lacking
inhibitor activity at concentrations up to 50 ug/ml.

Table 2

shows experiments using cathepsin B from both normal and
dystrophic livers, and the results show that it is indeed the
inhibitor which is altered in the dystrophic animal and not
the thiol proteases because the IDgQ values for TPI-n were
found to be the same against cathepsins B, H and L regardless
of the source of these

enzymes.

Also, these results indicate

that cathepsin B, H and L are "normal" in skeletal muscles of
dystrophic mice.
In the study reported here, the most pure preparations of
TPI—d showed significant activity against papain and cathepsin
H and L, whereas it was inactive against cathepsin B.

The

nature of the inhibitor substance in TPI—d preparations
(measured using papain) has not been determined but evidence
suggests that it might not be protein.

Thus, while the

"apparently" homogeneous TPI-d has inhibitor activity against
papain, cathepsins H and L, isoelectric focusing shows this
inhibitor to be separate from the TPI—d protein.

The latter

is inactive against cathepsin B and papain after purification
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on isoelectric focusing gels.
focusing is performed,

Thus, unless isoelectric

the defect in function of TPI—d is not

apparent except in the case inhere the cathepsin B is thetest
protease.

In contrast to our findings with mice, Kominami and

coworkers have found high levels of thiol protease inhibitor
activity in extracts from dystrophic hamster muscle assayed
using cathepsin H (Kominami et al., 1984).

The apparent

increases in TPI levels in muscle extracts of dystrophic
hamsters may reflect a different biochemical lesion in
hamsters than in mice,

since the dystrophic hamsters

(BIO-14.6) used in their experiments were from a
cardiomyopathic line.

Alternatively, the high level of TPI

activity observed in protein preparations from these hamsters
could be due to the use of cathepsin H as the test protease.
In crude extracts of skeletal muscle of dystrophic hamsters of
strain Bio. 14.6, the elevated thiol protease activity appears
to be the result of enhanced protein synthesis (Katanuma et
al., 1983b).

Perhaps in dystrophic hamsters, muscle necrosis

occurs by a different route than in dystrophic mice.
In muscle preparations from normal mice the protease
inhibitor of pi 4.5 (TPI-n) was found to be functional against
papain and cathepsin B, while in muscle preparations from
dystrophic mice the protease "inhibitor" of pi 4.5 (TPI-d) was
non—functional against these thiol proteases (see Table 2). An
inhibitor activity at pi 4.9 was observed in the dystrophic
muscle which becomes detectable after isoelectric focusing of
TPI-d.

This inhibitory activity was also detected in carrier
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female mice (+/dy) heterozygous for the disease but not in
normal retired female breeders <+/+) of the same age (Fig.
15).

The source of the pi 4.9 inhibitor activity in muscle

which is active against papain (and perhaps cathepsin H and L)
is not known.

Whatever its source, if it is a protein it has

a high specific inhibitor activity against papain. Attempts to
trace the origin of this inhibitor have not been made,
however, its source could be from macrophages because
macrophage infiltration is observed widely in diseased tissues
(Lenney, 1980).

Recently Kominami et al. (1984) demonstrated

the presence of protease inhibitors in macrophages from
dystrophic hamsters.

It is known that while the dystrophy

gene is expressed initially in muscle, its effects are also
detectable in non—muscle cells such as erythrocytes,
fibroblasts and lymphoblasts (Sweeney and Brown, 1981; Davis
et al., 1982; Pimplikar and Malhotra, 1983).

Reasons why the

product of dystrophy gene should be manifested to a greater
extent in muscle than in other tissues are not known.

Perhaps

in non—target tissues the dystrophy gene is inactive, while
another gene coding for a similar protein is active.

However,

since our knowledge of the regulation of intracellular protein
breakdown is not as advanced as our overall knowledge of
protein synthesis, the protein catabolic mechanism may be
regulated differently in muscle than in other tissues where
protein turnover rates differ and the dystrophy gene product
is of greater importance (Mil 1ward et al., 1980;

Garber et

al., 1980a). While the function of TPI’s in healthy
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individuals is not clearly understood (Dean, 1979), it is
possible that TPI’s normally function by protecting the cell
from inappropriate intracellular proteolysis.
It is not known whether the thiol proteases that damage
the structural and soluble components of the myotubes and
other cells are cytosolic or lysosomal in origin, but at least
one report indicates that lysosomes from dystrophic animals
have altered membrane properties which may allow some
lysosomal thiol proteases to leak into the cytosol in
dystrophic but not normal individuals (Davis et al.,

1982).

Circulating macrophages and other protease rich cells
(fibroblasts) in muscle may also contribute proteases to cells
lacking functional TPI’s compounding the problem for myoblasts
and myotubes in dystrophic animals (Kar and Pearson, 1978).
In this study it is assumed that

the TPI isolated from the

whole muscle is myocytic in origin.

Evidence from other

workers has shown that thiol protease inhibitors in muscle are
located mainly in the cytosol of post—fusion myoblasts
(myotubes) and not in fat or connective tissue cells (Lenny,
1980).
That muscular dystrophy in most animals appears to be
closely linked to a defect in the protease regulatory
mechanism is a view supported by several studies using
protease inhibitors.

Libby and Goldberg (1978) and Sher et

al. (1981 ) have shown that leupeptin, a thiol protease
inhibitor, significantly reduces the rate of protein
degradation in mice with hereditary muscular dystrophy, while
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McGowan et al. (1976) and Stracher et al. (1978; 1979) made
similar observations using muscle and cells from dystrophic
chickens.

However, Hudecki et al. (1981) were unable to

observe any beneficial effects of leupeptin on dystrophic
chickens.

Recently Tsuji and Matsushita (1986) have shown

beneficial effects of bestatin, a diaminopeptidase inhibitor,
on dystrophic mice with elevated levels of diaminopeptidases.
(The exact role of diaminopeptidases in myofibrillar protein
turnover is, however, not understood).

Bestatin is a small

molecular weight immunomodifier originally isolated from
Stregtgmyces_giivgretivuii.

It is known to have a potent

inhibitor effect on aminopeptidase B and leucine
aminopeptidase existing exclusively in the cell membrane, and
to attach to the cell membrane of macrophages, T-lymphocytes
and other mammalian cells and modify their functions (Muller
et al., 1982).

If immunological deficiencies play a major

role in the pathology of muscular dystrophy, then it may be
that the immuno—potentiating action of bestat in is conducive
to controlling the disease process.

Thus despite certain

equivocal data on the effectiveness of protease inhibitors in
dystrophic animals, it appears that lysosomal proteases,
especially the thiol proteases, play a key role in the onset
and progression of muscle degeneration in dystrophic animals.
The observations made in this study show that the TPI in
dystrophic mouse muscle is functionally defective supports
this conclusion.
The reason(s ) for the loss of activity in the TPI protein
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of skeletal nxascle of dystrophic mice is not yet known.

It

may be due to an amino acid substitution in TPI—n which
affects the molecular conformation of the protein, but not its
pi, or it may be due to a post—translational

modification of

one or more amino acids in the molecule. Recent data from an
amino acid analyses of the TPI protein carried out in
collaboration with Dr. M. Bloom at the University of Toronto
have shown one less tyrosine residue and one or two fewer
histidine residues in TPI-d compared to TPI-n.

Also, there

are two additional lysine residues in TPI-d compared to
TPI-n.

The N—terminal amino acids are blocked in both TPI-n

and TPI—d. Since both TPI-n and TPI-d

resist hydrolysis by

trypsin at high enzyme to substrate ratios (1 :2 0 ) and long
incubation periods (48 hours at 37 C), comparative analysis of
the tryptic fragments of the TPI’s have not been carried out.
Also, glycoprotein analyses were negative for both TPI-n and
TPI-d which indicate that the differences in inhibitor
activity are not due to differences in their carbohydrate
moiety.

Structural studies, including amino acid sequence

analyses to identify the altered or missing amino acid(s) in
the TPI of animals with hereditary muscular dystrophy remain
to be done.
The appearance of inhibitor activity at pi 4.9 in
extracts from skeletal muscles of carrier females heterozygous
for the disease opens up the possibility for carrier
detection, since carrier detection of Duchenne muscular
dystrophy is still a significant problem (Garden—Medwin, 1983;
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Dubowitz, 1982).

Despite the introduction of new techniques

with more or less success, a significant percent of carriers
remain without diagnosis and, consequently, the disease goes
on being transmitted.

The introduction recently of a

radioimmunoassay for serum myoglobin has opened up new
perspectives for the detection of carriers with muscular
dystrophy because "leaky" plasma membranes in patients and
carriers would allow abundant loss of myoglobin from the
skeletal muscles into serum.

This assay has been used as an

alternative to the use of creatine kinase for carrier
detection (Sabria—Lea1, 1986).

However, this assay is not

unique to muscular dystrophy because myoglobin release into
serum has been observed also in myocardial infarction
(Adornato et al., 1978).

The findings described in this

dissertation for dystrophic mice may serve as a model for
human muscular diseases including Duchenne muscular dystrophy
and if so, an effective assay may be developed to screen
potential carriers of the disease for the presence of either
the defective TPI or the pi 4.9 inhibitor component in muscle
extracts.
Recent reports on the isolation of portions of Duchenne
muscular dystrophy gene (Monaco et al., 1986; Worton et al.,
1984) are also

important and relevant to the problem at hand.

Although the product(s ) of the cloned gene fragments have not
been identified, it will be interesting to see whether the
defective gene in Duchenne muscular dystrophy codes for a
protease inhibitor as suggested by the work in this
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dissertation.
As the amino acid sequence data of mouse muscle TPI—d
become available,

labelled DNA probes can be constructed

to detect and isolate the dystrophic and normal genes from
restriction enzyme digests of genomic DNA.

The desired

restriction fragments can then be cloned in a suitable
phage/piasmid system.

The nucleotide sequence of the cloned

(defective and normal) genes would help to identify the
altered/missing nucleotide(s) in the dystrophy gene, and allow
in_si,tu hybridization to localize the TPI gene.
Muscular dystrophy in mice of strain 129/ReJ(dy/dy) is a
disease transmitted by a single autosomal recessive factor
(West and Murphy, 1960).

However, in many of its clinical

features it resembles the Duchenne form of muscular dystrophy
(DMD) affecting human males.

Thus if the TPI gene in

dystrophic mice is functionally inactive or defective, the
primary lesion causing the onset and progression of the
Duchenne form of muscular dystrophy in humans might be
(similar or identical) to the one in mice.

The significance

of the findings reported in this dissertation have enhanced
our understanding of the biochemical basis of muscular
dystrophy to the point where a cure for the disease may be in
sight.

Should future research on dystrophic muscle in humans

reveal a defect in the TPI protein similar to that found in
mice, then a major effort should be mounted to develop and
test additional protease inhibitors in search of a treatment
to ameliorate this debilitating disease until such time as the
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frequency of the disease in humans can be reduced to the
lowest level possible or the disease eliminated completely.
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